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It is known that the receptor for platelet-derived growth factor (PDGF) activates phospholipase C (PLC) by phospho:ylating the yl isoform of 
PLC with the receptor protein-tyrosine kinase (PTK), whereas aguanine nucleotide-binding protein participates as a transducer in the PLC activa- 
tion through the receptors for vasopressin, bombesin and prostag!andin Fr. (PGF,,). We have shown in a rat fibroblast line that staurosporine 
is a potent PTK inhibitor capable of clearly discriminating the two types of receptor-stimulated C3+ mobilization and, by inference. PLC activation: 
the response triggered by PDGF was completely inhibited, whereas the responses triggered by vasopressin, bombesin and PGF,, were not affected 
at all. The Ca2+ mobilization in human T and B cell lines induced by anti-CD3 and anti-immuaoglobulins (Ig) was completely suppressed by stau- 
rosporine. The results indicate that the PTK aotivity plays an essential role in the PLC activation through the T cell receptor/CD3 complex and 
through membrane Ig. 
T cell receptor; Membrane immunoglobulin; Staurosporine; Calcium ion mobilization; Platelet-derived growth factor; Protein-tyrosinc kinase 
1. INTRODUCTION 
Receptor-stimulated activation of phospholipase C 
(PLC) is one major pathway of signal transduction 
through cell-surface receptors. The signaling by the 
PLC activation can be most easily monitored by 
measuring an increase in the intracellular free Cat+ 
concentration ([Ca’+]i), the initial spike component of 
which is induced by inositol 1,4,%trisphosphate [ll. Two 
mechanisms are-known in the coupling of cell-surface 
receptors to PLC [2-41. Many receptors with seven 
membrane-spanning segments including those for 
vasopressin, bombesin, and prostaglandin Fza (PGFz,) 
activate an isoform of PLC, presumably PLC-0 [S], by 
coupling to a heterotrimeric guanine nucleotide-binding 
protein (G-protein), which functions as a transducer 
between the receptors and PLC [2,3,6]. The second 
mechanism has been found in the PLC activation by 
receptor protein-tyrosine kinases (PTK) [4]. Platelet- 
derived growth factor (PDGF) activates the yl isoform 
of PLC by phosphorylating the PLC with the PDGF- 
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receptor PTK, making PLC-~1 capable of hydrolyzing 
phosphatidylinositol 4,5-bisphosphate bound to pro- 
filin [7]. 
Cross-linking by antibodies of the antigen-specific 
receptors on T and B lymphocytes, T cell receptor 
(TCR)/CD3 complex and membrane immunoglobulins 
(mIg) with its associated proteins, activates PLC [8,9], 
resulting in an increase in [Ca” ]i. The mechanism of 
the PLC activation through the TCR/CD3 complex is 
poorly understood. Participation of the PTK activity 
has been indicated on the basis of suppression of the 
TCR/CD3-mediated activation of PLC by herbimycin 
A and genistein [IO-121. In the PLC activation through 
mIg, a role for a G-protein has been shown based on the 
effects of y-thio and &thio analogues of guanine 
nucleotides on the activation [13-151. However, it was 
recently reported that herbimycin A and genistein also 
block the PLC activation through mIg [12,16], which 
indicates that a PTK is somehow involved in the PLC 
activation through the B cell antigen receptor. 
In this paper, we assessed the susceptibility of the 
response with a rise in [Ca’+ ]I (hereafter referred to as 
the Ca’+ response) in human T and B cell lines to the 
inhibition by staurosporine, genistein, and iso- 
quinolinesulfonamidcs, H-7 and H-8. Staurosporine, a
microbia1 alkaloid, is known to be a potent inhibitor of 
a variety of protein kinases including PTKs [17-201. 
The susceptibility to these drugs of the Ca2 * responses 
in a rat fibroblast line, WFB, induced by PDGF, 
vasopressin, bombesin, and PGFz, was also assessed 
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under the same conditions; staurosporine clearly 
discriminated the two mechanisms of PLC activation 
dependent or independent on a PTK. Our results in- 
dicate that the PTK activity plays an essential role in the 
PLC activation through the TCRKD3 complex and 
through mIg. 
2. MATERIALS AND METHODS 
2.1. Muterink 
0KT3 Monoclonal antibody and PDGF were prepared as described 
previously 121.221. Commercial sources of chemicals and antibodies 
were as follows: arginine-vasqpressin (367 U/mg), bombesin, 
affinity-purified F(ab’)? goat anti-human IgG (y-chain-specific), and 
affinity-purified goat anti-human IpM @-chain-specific), Sigma; H-7 
and H-8, Scikagaku Kogyo (Tokyo); staurosporine, Boehringer 
Mannheim; genistein, Funakoshi Pharmaceuticals (Osaka); rabbit 
anti-mouse Ig, Dakopatts. 
2.2. Cell c&lure and dete?minaGon of [Ccl’+ /i 
A human T cell line, Jurkat (clone E6-l), and human B cell lines, 
RPM1 8075 [23] and Daudi, were cultured in Iscove’s modified 
Dulbecco’s medium supplemented with 10% fetal calf serum as 
described previously [21]. The cells harvested at late log phase of 
growth were loaded with fluo-3 by incubating the cells (3 x 10’ 
cells/ml in serum-free medium) with 10 gM flue-3/acetoxymethyl 
ester (fluo-3 AM) at 23°C for 1 h. Flue-3 AM was added from a 
dimethyl sulfoxide solution containing 2 mM flue-3 AM and Pluronic 
F-127 (a non-ionic detergent) at 50 mg/ml. After loading, the cells 
were washed twice with HEPES-buffered saline, which contained I 
mM Ca’+, and then suspended in the saline at 2x lo6 cells/ml. 
WFB cells were cultured as described previously (21. The cells kept 
for 3 days after growth to confluence were loaded with fluo-3 by in- 
cubating the cells in monolayer with 20 gM flue-3 AM, added from 
the solution described above, in serum-free medium at 23°C for 2 h. 
After loading, the cells were washed twice with HEPES-buffered 
saline, harvested by scraping with a rubber policeman, washed again, 
and then suspended in the saline at 1.2x IO6 cells/ml. 
Flue-3 fluorescence from 1 ml of the cell suspension was recorded 
at 20°C with a Hitachi 650-10s fluorescence spectrophotometer. Ex- 
citation and emission wavelengths were 500 and 530 nm. Ligands used 
in stimulating cells were added in a volume of I-5 @I to 1 ml of 
fluo-3-loaded cells at the following doses: 108 ng of the PDGF 
preparation described previously [2,22], 1.2 mU of vasopressin, 40 
pmol of bombesin, 1 nmol of PGFz”, 1 Fcg of 0KT3, 50 /tg of anti- 
mouse Ig, 2 fig of anti-human IgG F(ab’)~, and I pg of anti-human 
IgM. Staurosporine (I mM) in dimethyl sulfoxidc was added 1 min 
before the lignnd addition at I pl per ml of cell suspension. Genistein 
(10 mg/ml) in dimethyl sulfoxidc wasadded 15 min before the ligand 
addition at 1 .I ~1 per ml of cell suspension. H-7 (IO mM) and H-8 (10 
mM) in water were added 6 min beforcd the ligand addition at 3 ~1 per 
ml of ccl1 suspension. 
3. RESULTS 
3.1. Effects of protein kinase inhibitors on the Cd’ 
respottses of a rat fibloblast line, WFB 
WFB cells respond to the stimulation by PDGF, 
vasopressin, bomb&n, and PGFz,, with the PLC ac- 
tivation and an increase in [Ca’ *]i [2]. The susceptibili- 
ty of the Ca2 + responses in WFB cells to the inhibition 
by staurosporine, gcnistein, H-7, and H-8 was deter- 
mined by the use of a fluorescent Ca2+ indicator, fluo-3 
1241. Flue-3 was chosen in place of fura- for its longer 
excitation and emission wavelengths to avoid an in- 
tcrfcrcnce by the fluorcsccnce of staurosporine. All 
Ca’ + responses reported in this paper were measured at 
2O’C to avoid and excessive leak of flu03 from the cells 
at higher temperature. The Ca*+ response to PDGF 
was completely inhibited by 1 PM staurosporine added 
1 min before the PDGF addition and by 4OrM genistein 
(Fig. 1). H-7 and H-8, inhibitors of protein kinase C 
and CAMP-dependent protein kinase [25], had no 
marked effects on the Ca2 * response to PDGF at 30 PM 
(Fig. 1): a concentration high enough for the inhibition 
by these drugs [25]. The Ca2 + response in WFB cells to 
vasopressin was not inhibited by staurosporine, H-7, or 
H-8 under the same conditions as described above (Fig. 
2) Genstein had a small inhibitory effect on the Caz’t 
response to vasopressin (Fig. 2). The Ca2 + responses in 
WFB cells to bombesin and PGF2, were not affected at 
all by staurosporine, H-7, or H-8 and suppressed to a 
limited extent by genistein as found in the response to 
vasopressin (data not shown). These results indicate 
that staurosporine is an inhibitor capable of clearly 
discriminating two types of the receptor-stimulated 
PLC activation either dependent or independent on a 
PTK. 
3.2. Effects of protein kinase inhibitors on the Cd+ 
responses of human T and B cell lines 
The susceptibility of Ca2+ responses in human T and 
B cell lines to the inhibition by staurosporine was deter- 
mined under the same conditions as used in WFB cells. 
The Ca2 + response of a human T cell leukemia line, 
Jurkat, to anti-CDS, 0KT3, was completely inhibited 
by 1 PM staurosporine (Fig. 3). Genistein at 40 FM in- 
hibited the response to some extent but the inhibition 
was not complete (Fig. 3). H-7 and H-8 did not have 
any obvious effect on the Cat+ response of Jurkat cells 
(Fig. 3). 
Pig. 1. Effc<tsof ntnurospnrlnc, genistcin, l-l-7 uacl fl-8 on the PDGF- 
induscd Ca’ * rcsportsc in WFl? iells. 
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Fig. 2. Effects of staurosporine, genistein, H-7 and H-8 on the 
vasopressin-induced Ca*+ response in WFB cells. 
The Car + response of an Epstein-Barr virus- 
transformed human B cell line, RPM1 8075, to anti- 
human IgG was completely inhibited by 1 pM 
staurosporine (Fig. 4). Genistein at 40 ,uM inhibited the 
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Fig. 4. Effects of staurosporine. genistein, H-7 and H-8 on the anti- 
human IgG (onli r)-induced Ca*’ response in RPM1 8075 ceils. 
response to a limited extent (Fig. 4). H-7 and H-8 did 
not have any obvious effect on the Ca2+ response of 
RPM1 8075 cells (Fig. 4). Another human B cell line, 
Daudi, responded to anti-human IgM with an increase 
in [Cat+];. Daudi cells did not respond to anti-human 
IgG with an increase in [Ca’+]i, nor RPM1 8075 cells to 
anti-human IgM. The effects of staurosporine and 
genistein on the Ca2+ -response in Daudi cells were 
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almost identical with those found in Jurkat cells and 
RPM1 8075 cel!s (Fig. 5). In Daudi cells, a small 
enhancement of the Ca” + response by H-7 and H-8 was 
observed (Fig. 5). 
4. DISCUSSION 
The receptor-stimulated activation of PLC in such 
ligand-receptor systems as those used in this study 
[2,4,8,9,11,16,21,22,26,27] can be indirectly monitored 
by the Ca*‘. responses, which are by far more sensitive 
and convenient than the assay of [‘Hlinositol 
phosphate release from the cells labeled with myo- 
t3H]inositol. The results presented in this paper indicate 
that the two types of receptor-stimulated increase in 
;Ca*+]i and, by inference, receptor-stimulated activa- 
tion of PLC can be clearly distinguished by the use of 
staurosporine: the responses mediated by a PTK are 
completely inhibiied by staurosporine, whereas those 
mediated by a G-protein are not affected at all. The 
mechanism of this drug effect can be attributed to its 
potent inhibitory effect on PTKs: half maximal concen- 
tration for the inhibition by staurosporine has been 
reported to be 6.4 nM for pp60v~s’c PTK, while that for 
protein kinase C and CAMP-dependent protein kinase is 
2.7 nM and 8.2 nM, respectively [17-191. Herbimycin A 
and genistein, but not staurosporine, have been used by 
other investigators as PTK inhibitors to examine the 
participation of a PTK in the receptor-stimulated ac- 
tivation of PLC [ lo-12,161. Addition of staurosporine 
at 1 ,xM and 1 min before the ligand addition completely 
inhibited the PTK-dependent Ca* + responses (Figs. 
1,3,4 and 5), whereas with herbimycin A an incubation 
of cells at l-10 FM for more than 10 h is necessary to 
suppress the PTK-dependent increase in [Cat+ ]i and ac- 
tivation of PLC [ 11,12,16]. Herbimycin A may not be 
a classic competitive inhibitor; the inhibition appears to 
require PTK degradation [11,28]. 
It is difficult to obtain enough inhibition by genistein 
due to a low potency and a limited solubility of the 
drug; in our optical measurements i  was not possible to 
add genistein at 100 pM or more. The concentration of 
genistein for half maximal inhibition was 2.5 FM for 
EGF receptor PTK and 28 PM for pp60’~“” PTK 
[29,30]; this difference in the inhibitory effect of gcnis- 
tein between receptor PTK and non-receptor PTK may 
possibly account for complete suppression of the 
PDGF-triggered Cat+ response by 40 PM genistein 
(Fig. 1) and for partial suppression of the 
OKT3-triggered and anti-Ig-triggered Ca*+ responses 
by the same concentration of genistein (Figs. 3,4 and 5). 
The results hown in Figs. 3, 4 and 5 demonstrate that 
the Ca2’ responses of human T and B cell lines induced 
by anti-CD3, anti-IgG and anti-1gM arc complctcly in- 
hibited by stnurosporinc. By deduction from the results 
in WFB cells, it is possible to conclude that the PTK ac- 
tivity plays an essential role in the PLC activation 
through the TCR/CD3 complex and through mIgG and 
mIgM. H-7 and H-8 had no inhibitory effect on any of 
the Ca*+ responses tudied; this is consistent with the 
assumption that PTKs are the target of the inhibition by 
staurosporine in the Ca*’ responses. The PLC activa- 
tion through the TCR/CD3 complex and mIg can be 
grouped into a new type of the receptor-stimulated ac- 
tivation of PLC, which is characterized, presumably, 
by the participation of nonreceptor PTKs in the coupl- 
ing of a receptor to PLC. Although the non-receptor 
PTKs involved in the signal transduction through this 
PLC pathway are not yet identified, pSafv” and ~56”~ 
are possible candidates for the non-receptor PTK 
mediating the PLC activation through the TCR/CD3 
complex [31]. 
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